Cosmo Pharma Renews Global Manufacturing Deal With Takeda For Ulcerative Colitis Drug

Realtime	Geld	Brief	Zeit
	25,620	26,030	28.08.
	25,700	25,950	28.08.

Realtime

Geld

Brief

Zeit

25,620

26,030

28.08.

25,700

25,950

28.08.

Cosmo Pharma Renews Global Manufacturing Deal With Takeda For Ulcerative Colitis Drug

DUBLIN (dpa-AFX) - Cosmo Pharmaceuticals N.V. (COPN.SW) announced the renewal of its multi-year manufacturing and supply agreement with Takeda.

As per the deal, Cosmo will continue producing Mesalazine MMX 1200 mg-marketed as Lialda in the USA and Mezavant in Europe-a once-daily oral treatment for ulcerative colitis.

Cosmo's advanced manufacturing site in Lainate (Italy) is approved by multiple regulatory authorities worldwide.

Copyright(c) 2025 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

Zeitenwende! 3 Uranaktien vor der Neubewertung

Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!

Hier klicken

Zeit	Aktuelle Nachrichten
Mi	Cosmo Pharmaceuticals N.V.: Cosmo Receives Positive CHMP Opinion for Winlevi(R) for Treatment of Acne in Adults and Adolescents, Following Successful Re-Examination	Dublin, Ireland--(Newsfile Corp. - August 27, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Medicines... ► Artikel lesen
08.08.	Cosmo Pharma Renews Global Manufacturing Deal With Takeda For Ulcerative Colitis Drug	DUBLIN (dpa-AFX) - Cosmo Pharmaceuticals N.V. (COPN.SW) announced the renewal of its multi-year manufacturing and supply agreement with Takeda.As per the deal, Cosmo will continue producing... ► Artikel lesen
08.08.	Cosmo und Takeda verlängern strategische Produktionsvereinbarung
08.08.	Cosmo Pharmaceuticals N.V.: Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis	Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of... ► Artikel lesen
06.08.	Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth Momentum	Dublin, Ireland--(Newsfile Corp. - August 6, 2025) - Cosmo Pharmaceuticals N.V. ("Cosmo") notes the recent market volatility following reports on potential U.S. tariffs on Swiss pharmaceutical companies.... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Cosmo Pharmaceuticals N.V.: Cosmo Receives Positive CHMP Opinion for Winlevi(R) for Treatment of Acne in Adults and Adolescents, Following Successful Re-Examination

Dublin, Ireland--(Newsfile Corp. - August 27, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Medicines...
► Artikel lesen

08.08.

Cosmo Pharma Renews Global Manufacturing Deal With Takeda For Ulcerative Colitis Drug

08.08.

Cosmo und Takeda verlängern strategische Produktionsvereinbarung

08.08.

Cosmo Pharmaceuticals N.V.: Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of...
► Artikel lesen

06.08.

Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth Momentum

Dublin, Ireland--(Newsfile Corp. - August 6, 2025) - Cosmo Pharmaceuticals N.V. ("Cosmo") notes the recent market volatility following reports on potential U.S. tariffs on Swiss pharmaceutical companies....
► Artikel lesen

Zeit	Aktuelle Nachrichten
Do	Takeda's Fruzaqla Publicly Reimbursed In Quebec For Treatment Of Metastatic Colorectal Cancer	TOKYO (dpa-AFX) - Takeda Canada Inc. Thursday announced that Fruzaqlatm (fruquintinib capsules) will now be reimbursed by Régie de l'assurance maladie for people in Quebec, under certain criteria... ► Artikel lesen
Do	Takeda's FRUZAQLA (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)
22.08.	What's Going On With Takeda Stock On Friday?
08.08.	Takeda, Cosmo extend partnership on ulcerative colitis treatment
08.08.	Cosmo Pharma Renews Global Manufacturing Deal With Takeda For Ulcerative Colitis Drug	DUBLIN (dpa-AFX) - Cosmo Pharmaceuticals N.V. (COPN.SW) announced the renewal of its multi-year manufacturing and supply agreement with Takeda.As per the deal, Cosmo will continue producing... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Takeda's Fruzaqla Publicly Reimbursed In Quebec For Treatment Of Metastatic Colorectal Cancer

TOKYO (dpa-AFX) - Takeda Canada Inc. Thursday announced that Fruzaqlatm (fruquintinib capsules) will now be reimbursed by Régie de l'assurance maladie for people in Quebec, under certain criteria...
► Artikel lesen

Takeda's FRUZAQLA (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)

22.08.

What's Going On With Takeda Stock On Friday?

08.08.

Takeda, Cosmo extend partnership on ulcerative colitis treatment

08.08.

Cosmo Pharma Renews Global Manufacturing Deal With Takeda For Ulcerative Colitis Drug